company background image
1731

Maywufa TWSE:1731 Stock Report

Last Price

NT$18.00

Market Cap

NT$2.4b

7D

-1.6%

1Y

-3.0%

Updated

01 Oct, 2022

Data

Company Financials
1731 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends2/6

1731 Stock Overview

Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan.

Maywufa Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Maywufa
Historical stock prices
Current Share PriceNT$18.00
52 Week HighNT$24.20
52 Week LowNT$16.60
Beta0.50
1 Month Change-3.74%
3 Month Change7.46%
1 Year Change-2.97%
3 Year Change36.36%
5 Year Change31.87%
Change since IPO-14.95%

Recent News & Updates

Shareholder Returns

1731TW Personal ProductsTW Market
7D-1.6%-5.8%-5.0%
1Y-3.0%-3.5%-18.0%

Return vs Industry: 1731 matched the TW Personal Products industry which returned -3.5% over the past year.

Return vs Market: 1731 exceeded the TW Market which returned -18% over the past year.

Price Volatility

Is 1731's price volatile compared to industry and market?
1731 volatility
1731 Average Weekly Movement2.9%
Personal Products Industry Average Movement5.7%
Market Average Movement5.1%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 1731 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 1731's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976n/an/ahttps://www.maywufa.com.tw

Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. It offers hair care products; health care products and food supplements; and mother and baby skin care products under the mustela brand. The company also provides pharmaceuticals and medical devices, such as PG2 Lyophilized injection for treatment of cancer-related fatigue; AmCad-UT Detection device, an ultrasound CAD for thyroid cancer detection; Bio-Three tablets for the treatment of mild diarrhea, abdominal pain, and constipation; and Cerebrolysin, a supplementary nutrient boost for patients who cannot ingest adequate food and patients who have difficulties in the digestion, absorption, synthesis, and utilization of proteins, as well as for patients suffering from severe trauma, burns, fractures, insufficient protein intake, or malnutrition.

Maywufa Fundamentals Summary

How do Maywufa's earnings and revenue compare to its market cap?
1731 fundamental statistics
Market CapNT$2.39b
Earnings (TTM)NT$159.49m
Revenue (TTM)NT$1.30b

15.0x

P/E Ratio

1.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1731 income statement (TTM)
RevenueNT$1.30b
Cost of RevenueNT$430.34m
Gross ProfitNT$868.36m
Other ExpensesNT$708.87m
EarningsNT$159.49m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.20
Gross Margin66.86%
Net Profit Margin12.28%
Debt/Equity Ratio0%

How did 1731 perform over the long term?

See historical performance and comparison

Dividends

6.5%

Current Dividend Yield

98%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 1731 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1731?

Other financial metrics that can be useful for relative valuation.

1731 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA8.2x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 1731's PE Ratio compare to its peers?

1731 PE Ratio vs Peers
The above table shows the PE ratio for 1731 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average22.7x
6703 Shiny Brands Group
14.4xn/aNT$2.0b
1796 GeneFerm Biotechnology
27.6xn/aNT$2.4b
1783 Maxigen Biotech
31.6xn/aNT$3.1b
8480 Taisun Int'l (Holding)
17.1xn/aNT$3.3b
1731 Maywufa
15xn/aNT$2.4b

Price-To-Earnings vs Peers: 1731 is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (22.7x).


Price to Earnings Ratio vs Industry

How does 1731's PE Ratio compare vs other companies in the Asian Personal Products Industry?

Price-To-Earnings vs Industry: 1731 is good value based on its Price-To-Earnings Ratio (15x) compared to the Asian Personal Products industry average (25.7x)


Price to Earnings Ratio vs Fair Ratio

What is 1731's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1731 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1731's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 1731 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1731 (NT$18) is trading above our estimate of fair value (NT$14.22)

Significantly Below Fair Value: 1731 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Maywufa forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.8%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Maywufa has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Maywufa's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Maywufa performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


15.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 1731 has high quality earnings.

Growing Profit Margin: 1731's current net profit margins (12.3%) are lower than last year (14.1%).


Past Earnings Growth Analysis

Earnings Trend: 1731's earnings have grown by 15.9% per year over the past 5 years.

Accelerating Growth: 1731's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1731 had negative earnings growth (-4.4%) over the past year, making it difficult to compare to the Personal Products industry average (-11.6%).


Return on Equity

High ROE: 1731's Return on Equity (8.3%) is considered low.


Discover strong past performing companies

Financial Health

How is Maywufa's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 1731's short term assets (NT$999.0M) exceed its short term liabilities (NT$457.7M).

Long Term Liabilities: 1731's short term assets (NT$999.0M) exceed its long term liabilities (NT$6.3M).


Debt to Equity History and Analysis

Debt Level: 1731 is debt free.

Reducing Debt: 1731 has no debt compared to 5 years ago when its debt to equity ratio was 11.8%.

Debt Coverage: 1731 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1731 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Maywufa current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


6.50%

Current Dividend Yield

Dividend Yield vs Market

Maywufa Dividend Yield vs Market
How does Maywufa dividend yield compare to the market?
SegmentDividend Yield
Company (Maywufa)6.5%
Market Bottom 25% (TW)2.6%
Market Top 25% (TW)7.0%
Industry Average (Personal Products)3.8%
Analyst forecast in 3 Years (Maywufa)n/a

Notable Dividend: 1731's dividend (6.5%) is higher than the bottom 25% of dividend payers in the TW market (2.59%).

High Dividend: 1731's dividend (6.5%) is low compared to the top 25% of dividend payers in the TW market (7%).


Stability and Growth of Payments

Stable Dividend: 1731's dividend payments have been volatile in the past 10 years.

Growing Dividend: 1731's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (97.5%), 1731's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (256.2%), 1731's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.3yrs

Average board tenure


CEO

Maywufa has no CEO, or we have no data on them.


Board Members

Experienced Board: 1731's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 1731?
Owner TypeNumber of SharesOwnership Percentage
Institutions430,8650.3%
General Public132,484,13599.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 1 shareholders own 0.32% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
0.32%
Dimensional Fund Advisors LP
430,865NT$7.8m0.19%no data

Company Information

Maywufa Company Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Maywufa Company Ltd.
  • Ticker: 1731
  • Exchange: TWSE
  • Founded: 1976
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: NT$2.392b
  • Shares outstanding: 132.92m
  • Website: https://www.maywufa.com.tw

Location

  • Maywufa Company Ltd.
  • No. 167, Fuxing North Road
  • 5th Floor
  • Taipei
  • 105
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1731TWSE (Taiwan Stock Exchange)YesCommon StockTWTWDAug 1999

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.